These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15502325)

  • 1. Preparation, crystallization and preliminary X-ray analysis of a complex between the Plasmodium vivax sexual stage 25 kDa protein Pvs25 and a malaria transmission-blocking antibody Fab fragment.
    Saxena AK; Singh K; Long CA; Garboczi DN
    Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):2054-7. PubMed ID: 15502325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystallization and preliminary X-ray analysis of the Plasmodium vivax sexual stage 25 kDa protein Pvs25, a transmission-blocking vaccine candidate for malaria.
    Saxena AK; Saul A; Garboczi DN
    Acta Crystallogr D Biol Crystallogr; 2004 Apr; 60(Pt 4):706-8. PubMed ID: 15039560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of Fab fragment of malaria transmission blocking antibody 2A8 against P. vivax P25 protein.
    Saxena AK
    Int J Biol Macromol; 2012 Jan; 50(1):153-6. PubMed ID: 22037467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission.
    Blagborough AM; Yoshida S; Sattabongkot J; Tsuboi T; Sinden RE
    Vaccine; 2010 Aug; 28(37):6014-20. PubMed ID: 20637303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran.
    Zakeri S; Razavi S; Djadid ND
    Acta Trop; 2009 Mar; 109(3):176-80. PubMed ID: 18950597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-reactivity studies of an anti-Plasmodium vivax apical membrane antigen 1 monoclonal antibody: binding and structural characterisation.
    Igonet S; Vulliez-Le Normand B; Faure G; Riottot MM; Kocken CH; Thomas AW; Bentley GA
    J Mol Biol; 2007 Mar; 366(5):1523-37. PubMed ID: 17229439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression, crystallization and preliminary structural analysis of the ectoplasmic region of apical membrane antigen 1 from Plasmodium vivax, a malaria-vaccine candidate.
    Vulliez-Le Normand B; Pizarro JC; Chesne-Seck ML; Kocken CH; Faber B; Thomas AW; Bentley GA
    Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):2040-3. PubMed ID: 15502321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.
    Sattabongkot J; Tsuboi T; Hisaeda H; Tachibana M; Suwanabun N; Rungruang T; Cao YM; Stowers AW; Sirichaisinthop J; Coleman RE; Torii M
    Am J Trop Med Hyg; 2003 Nov; 69(5):536-41. PubMed ID: 14695092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and mechanism of a transmission blocking vaccine candidate protein Pfs25 from P. falciparum: a molecular modeling and docking study.
    Sharma B
    In Silico Biol; 2008; 8(3-4):193-206. PubMed ID: 19032156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
    Ramjanee S; Robertson JS; Franke-Fayard B; Sinha R; Waters AP; Janse CJ; Wu Y; Blagborough AM; Saul A; Sinden RE
    Vaccine; 2007 Jan; 25(5):886-94. PubMed ID: 17049690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate.
    Tachibana M; Sato C; Otsuki H; Sattabongkot J; Kaneko O; Torii M; Tsuboi T
    Vaccine; 2012 Feb; 30(10):1807-12. PubMed ID: 22245309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystallization, preliminary X-ray diffraction study, and crystal packing of a complex between anti-hen lysozyme antibody F9.13.7 and guinea-fowl lysozyme.
    Lescar J; Riottot MM; Souchon H; Chitarra V; Bentley GA; Navaza J; Alzari PM; Poljak RJ
    Proteins; 1993 Feb; 15(2):209-12. PubMed ID: 7680133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystallization and preliminary X-ray analysis of Borrelia burgdorferi outer surface protein A (OspA) complexed with a murine monoclonal antibody Fab fragment.
    Li H; Lawson CL
    J Struct Biol; 1995; 115(3):335-7. PubMed ID: 8573475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T; Harakuni T; Sugawa H; Sattabongkot J; Kato A; Tachibana M; Torii M; Tsuboi T; Arakawa T
    Vaccine; 2011 Mar; 29(15):2720-6. PubMed ID: 21315699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification, crystallization and X-ray diffraction analysis of a recombinant Fab that recognizes a human blood-group antigen.
    Song SC; Xie K; Czerwinski M; Spitalnik SL; Wedekind JE
    Acta Crystallogr D Biol Crystallogr; 2004 Apr; 60(Pt 4):788-91. PubMed ID: 15039587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of streptococcal protein G in obtaining crystals of an antibody Fab fragment in complex with a meningococcal antigen.
    Derrick JP; Feavers I; Maiden MC
    Acta Crystallogr D Biol Crystallogr; 1999 Jan; 55(Pt 1):314-6. PubMed ID: 10089436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystallization and preliminary X-ray diffraction studies of a monoclonal antibody Fab fragment against foot-and-mouth disease virus and of its complex with the main antigenic site peptide.
    Verdaguer N; Mateu MG; Bravo J; Tormo J; Giralt E; Andreu D; Domingo E; Fita I
    Proteins; 1994 Feb; 18(2):201-3. PubMed ID: 8159669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmodium vivax: a monoclonal antibody recognizes a circumsporozoite protein precursor on the sporozoite surface.
    Gonzalez-Ceron L; Rodriguez MH; Wirtz RA; Sina BJ; Palomeque OL; Nettel JA; Tsutsumi V
    Exp Parasitol; 1998 Nov; 90(3):203-11. PubMed ID: 9806864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.